The results of EMPA-REG OUTCOME Trial assess the role of empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Read More »CREDENCE Trial Shows Renal and Cardiovascular Protection
Strong results motivate the ADA to update its Standard of Care for patients with diabetes.
Read More »Beware: Diuretics Can Increase Risk of Amputations
Adding a SGLT-2 inhibitor which acts as a diuretic can increase the risk.
Read More »Canagliflozin Study Stopped Early Due to Positive Results in Reducing CKD, Death and ESRD
Featuring exclusive comments from Dr. George Bakris
Studies are rarely stopped early; when it happens, we should take notice of the results.
GLP-1RA as Add-on Therapy to SGLT-2 Inhibitor
Combination treatment can help improve glucose levels in patients with elevated HbA1Cs.
Read More »Sedentary Behavior During Pregnancy and Neonatal Adiposity
Lifestyle intervention in pregnancy might reduce adverse effects of maternal obesity on neonatal adiposity.
Read More »First Dual SGLT-1/2 Inhibitor For Adults With Type 1 Declined Approval
Sanofi and Lexicon to continue any required studies in effort to move sotagliflozin forward.
Read More »John Buse Part 3, SGLT2 Inhibitors Effects On Amputations And Cardiovascular Disease
In part 3 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the heart complication and amputation risks on the greater population.
Read More »Association Between Use of Sodium Glucose Cotransporter 2 Inhibitors and Serious Adverse Effects
Study findings warrant cautious consideration and discussions about risk vs benefit when considering therapy.
Read More »Novel Use of SGLT-2 Inhibitors for Treatment of Early-Stage Lung Adenocarcinoma
Study assessed association of cancer and sodium glucose transporter 2 expression as well as potential benefit of SGLT-2 treatment.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.